Absci (NASDAQ: ABSI) is a generative AI drug creation company at the forefront of revolutionizing the therapeutic discovery process. Its Integrated Drug Creation™ platform synergizes cutting-edge artificial intelligence models with scalable wet-lab technologies to design, build, test, and discover novel biologic drug candidates. Absci's mission is to significantly accelerate the pace of drug discovery and development, aiming to bring more effective medicines to patients by translating innovative ideas into viable drugs with unprecedented speed and a higher probability of success. They focus on creating next-generation therapeutics through a deep understanding of protein function and design.
The headquarters serves as Absci's primary hub for research and development, integrating advanced AI research with extensive wet-lab operations for its Integrated Drug Creation™ platform. It also houses corporate, administrative, and operational functions.
The facility features custom-designed, state-of-the-art laboratories equipped for high-throughput screening, synthetic biology, protein engineering, and data sciences. It's engineered to support Absci's unique de novo AI drug creation processes and large-scale data generation.
Absci fosters a work culture centered on innovation, intense collaboration between computational scientists and bench biologists, and a shared passion for solving complex biological challenges. The environment is dynamic and mission-driven, encouraging scientific rigor and embracing cutting-edge technological advancements.
The Vancouver headquarters is critical to Absci's operational strategy, concentrating its core proprietary technologies, advanced research capabilities, and a significant portion of its specialized scientific talent. Its location offers access to a growing life sciences community and talent pool.
While its primary physical research and corporate operations are based in the United States (Vancouver, WA, and New York, NY), Absci's impact and collaborations are global. The company engages in strategic partnerships with pharmaceutical and biotechnology companies worldwide, applying its AI-driven drug creation platform to diverse therapeutic targets. Its technology and drug candidates have the potential for global health impact, addressing unmet medical needs across various international markets.
18181 SW Lower Boones Ferry Rd
Vancouver
WA
USA
Address: 3 World Trade Center, 175 Greenwich St, New York, NY 10007
Serves as a focused center for pioneering AI research and algorithm development, directly supporting and enhancing the drug discovery capabilities of the main Vancouver operations. It aims to attract top-tier AI talent and foster breakthroughs in computational drug creation.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Absci' leadership includes:
Absci has been backed by several prominent investors over the years, including:
In the past 12 months, Absci has strengthened its executive team with key hires in operations and finance, and seen a transition in its Chief Scientific/Innovation Officer role. These changes support the company's strategic focus on scaling its AI-driven drug creation platform.
Discover the tools Absci uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Absci commonly utilizes the [first initial][last name]@absci.com email format. This pattern is prevalent in many technology and biotechnology companies, allowing for relatively straightforward professional communication. For example, an employee named Jane Doe would likely have an email address such as jdoe@absci.com.
[first_initial][last]@absci.com
Format
jdoe@absci.com
Example
85%
Success rate
Absci Press Release (via Business Wire) • May 28, 2024
Absci announced it will present new data showcasing its capabilities in de novo generative AI antibody design, including wet lab validation of these computationally derived antibodies. The presentations are scheduled for the PEGS Boston Summit and The Protein Engineering Summit Europe (PEGS Europe), highlighting advancements in creating therapeutic candidates with high success rates....more
Absci Press Release (via Business Wire) • March 7, 2024
Absci reported its financial results for the fourth quarter and full year ended December 31, 2023. The company also provided a corporate update, highlighting progress in its drug creation programs, advancements in its AI platform, and ongoing strategic partnerships. Key achievements included initial de novo antibody designs and progression of partnered programs....more
Absci Press Release (via Business Wire) • February 20, 2024
Absci announced the appointment of Laurens Kleijn, Ph.D., as its Chief Operating Officer. Dr. Kleijn brings extensive experience in biopharmaceutical operations and development, and will be responsible for scaling Absci's operations, enhancing its platform capabilities, and advancing its internal and partnered pipeline programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Absci, are just a search away.